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Abstract
Previous work in our laboratory has described several pro-angiogenic short peptides derived from endothelial extracellular
matrices degraded by bacterial collagenase. Here we tested whether these peptides could stimulate wound healing in vivo.
Our experiments demonstrated that a peptide created as combination of fragments of tenascin X and fibrillin 1 (comb1)
applied into cranial dermal wounds created in mice treated with cyclophosphamide to impair wound healing, can improve
the rate of wound closure. Furthermore, we identify and characterize a novel peptide (UN3) created and modified from two
naturally-occurring peptides, which are present in human platelet-rich plasma. In vitro testing of UN3 demonstrates that it
causes a 50% increase in endothelial proliferation, 250% increase in angiogenic response and a tripling of epithelial cell
migration in response to injury. Results of in vivo experiments where comb1 and UN3 peptides were added together to
cranial wounds in cyclophosphamide-treated mice leads to improvement of wound vascularization as shown by an increase
of the number of blood vessels present in the wound beds. Application of the peptides markedly promotes cellular
responses to injury and essentially restores wound healing dynamics to those of normal, acute wounds in the absence of
cyclophosphamide impairment. Our current work is aimed at understanding the mechanisms underlying the stimulatory
effects of these peptides as well as identification of the cellular receptors mediating these effects.
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Introduction
Despite significant progress that has been achieved in our
understanding of normal wound healing process and the
pathologies that lead to wound chronicity, chronic wounds of
differing etiology remain a significant health care burden affecting
over 5 million people annually in the United States, alone [1]. In
addition, acute and combat-associated wounds cause approxi-
mately 330,000 hospitalizations in this country alone [2,3].
The importance of endogenous platelets during the early phase
of the course of wound healing has been known for decades. Early
on platelets accumulate at the site of injury, and participate in
blood clotting and inflammatory cascades releasing interleukin 1b
(IL-1b) and IL-8 necessary for monocyte adhesion and neutrophil
activation respectively [4–6], Furthermore, activated platelets
release key cellular survival factors, such as platelet derived
growth factor (PDGF), vascular endothelial growth factor (VEGF)
and epidermal growth factor [7,8] which stimulate cellular
migration, proliferation and angiogenesis necessary for successful
wound healing. Recently [9], it has been suggested that exogenous
platelets and platelet products, including platelet rich plasma
extracts, might be used for stimulating wound healing as well. This
work is aimed at characterization of small peptides derived from
endothelial extracellular matrices and extracts of platelet rich
human plasma that could be used as stimulators of cellular
responses to injury. We test a hypothesis that similarly to native
platelet products, platelet-rich plasma derived peptides (PDP)
would stimulate cellular proliferation, migration and morphogen-
esis. Furthermore in this study we expanded our knowledge about
another biologically active peptide isolated from endothelial
extracellular matrices degraded by bacterial collagenase, which
was previously identified in our laboratory [10]. PDP and
extracellular matrix derived peptides (EDP) are tested in several
in vitro assays and in a mouse model of impaired wound healing.
Results reveal that the peptides could be used as separate entities
or in combination to stimulate cellular responses to injury both in
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32146vitro and in vivo. We demonstrate increased wound re-
epithelialization, granulation tissue formation and restoration of
wound healing ability in animals whose healing responses had
been compromised by cyclophosphamide treatment.
Materials and Methods
Ethics Statement
All animal protocols and experiments were approved by the
Subcommittee on Research Animal Care of Massachusetts
General Hospital or Institutional Animal Care and Use Commit-
tee at Tufts University and were performed in accordance with
NIH guidelines.
Cell culture
Bovine capillary endothelial cells (BCEC) were cultured as
previously described [11]. Human capillary endothelial cells were
grown in DMEM supplemented with 5% fetal bovine serum
(Atlanta Biologicals, Inc., Lawrenceville, GA) and antibiotics
(Invitrogen, Carlsbad CA).
Adult normal human epidermal keratinocytes (NHEK) were
purchased from Lonza (Walkersville, MD) and grown in serum
free keratinocyte growth media supplemented with human
recombinant epidermal growth factor (hrEGF) and bovine
pituitary extract (Invitrogen, Carlsbad CA) as per the manufac-
turer’s instructions.
Human spontaneously transformed keratinocytes (Hacat) cells
were provided by Dr. Garlick (Tufts University, Boston, MA) and
cultured in DMEM supplemented with 10% fetal bovine serum
(Atlanta Biologicals, Inc., Lawrenceville, GA) and antibiotics
(Invitrogen, Carlsbad CA).
Human blood platelet extracts and lysate preparation
Blood platelet extracts were prepared as follows. Pooled donor
platelet rich plasma was obtained from the South Texas Blood and
Tissue Center (San Antonio, TX), centrifuged at 4 C for 15–
20 min at 5000 rpm. Platelet poor plasma (supernatant) was
discarded and the pellet fraction was reconstituted using fresh
frozen plasma, resulting in a platelet count of between 250,000 to
4,500,000 platelets per milliliter. The platelets were gently rotated
to mix the contents and then snap frozen in liquid nitrogen prior
to lyophilization. Multiple lots of pooled platelets were prepared in
this manner and the lyophilized material from each lot was
reconstituted with sterile PBS to approximately 25 mg/ml protein
prior to fractionation or addition to cells as described below.
Blood bank platelet lysate was prepared from platelets acquired
from Tufts Medical Center Blood Bank. Platelets were lysed using
a saline solution containing 0.3% sodium citrate, 0.9% NaCl in
10 nM NaPO4, pH 6.5, centrifuged, resuspended in the same
solution, centrifuged three more times, and frozen for storage.
Gel filtration and ion-exchange chromatography [12]
Lyophilized extracts were reconstituted in sterile PBS at 25 mg/
ml and applied onto a 41 cm column filled with G-150 Sephadex
beads (Sigma-Aldrich, St. Louis, MO).
Samples were run at flow rate 4.5 ml/hr and collected using a
fractioncollector(BioRad,Hercules,CA).Fractionatedsampleswere
diluted with 0.02 M NaPO4 pH 7.2, mixed with DEAE-cellulose
(Sigma-Aldrich, St. Louis, MO) for 30 minutes, and centrifuged for
1 min at 4 C in a microfuge (12 kg). The proteins were eluted as
follows. After removing the supernatant, 0.05 M NaCl was added to
samples, mixed for 10 min, and centrifuged. Sodium chloride
solutions of different concentrations (0.10 M, 0.15 M, 0.50 M,
1.0 M) were subsequently added to DEAE-cellulose, mixed and
centrifuged. The supernatants containing different protein fractions
were collected, and either applied to cells after sterile dialysis vs. PBS
or subjected to gel electrophoresis as below.
Gel electrophoresis
Prior to SDS-PAGE, platelet extracts, fractions, or lysates were
dialysed at 4 C to remove salts and then resuspended in sample
buffer containing 2% SDS, 125 mM Tris-Cl, pH 7, 10% glycerol,
2% 2-mercaptoethanol and bromophenol blue. After electropho-
resis the gels were stained overnight with 0.25% Coomassie Blue
in 50% methanol, 10% acetic acid and destained in the same
alcohol solution without the dye. Alternatively, the gels were silver
stained with 20% silver nitrate solution and washed several times
with distilled water. Developer solution containing 0.005% citric
acid, 0.05% formaldehyde was then added to the gels. Once bands
appeared stop solution of 5% acetic acid was added. Images of
both Coomassie and silver stained gels were taken using UVP
BioChemi HR camera (UVP LLC, Upland, CA).
Western blotting
Lyophilized or solubilized and dialysed samples derived from
platelet extracts, human plasma- and extracellular matrix-derived
peptides were resuspended in a sample buffer and subjected to
SDS-PAGE as above. Proteins were then transferred to a
nitrocellulose membranes (Whatman Inc., Piscataway, NJ) and
probed as previously published [13] with anti-myosin II antibody
(from I. Herman, Tufts University School of Medicine; 1:100)
followed by goat anti-rabbit HRP-conjugated secondary antibody
(Santa Cruz Biotechnology, Santa Cruz, CA).
Identification of platelet-rich plasma derived peptides
and ECM-derived peptides
In vitro bioassays were used to determine which fractions
possessed growth promoting, migration enhancing and/or angio-
genesis-inducing activities. These bioactive fractions determined
by in vitro experiments were then subjected to SDS gel
electrophoresis prior to Coomassie staining band excision and
analysis by MS/MS mass spectrometry as previously described
[10]. Results of mass spectrometric analysis revealed the presence
of several protein fragments, greater than 90% of which were
known and less than 5% were human derived peptides of
unknown function (UN). Two of these fragments, which we
named UN1 and UN2, together with a third peptide (UN3) that
we created as a fusion between UN1 and UN2 joined together
with a linker amino acid and synthesized at Tufts University Core
Facility (TUCF).
ECM-derived peptides were identified as described previously
[10] and synthesized at TUCF.
Epithelial migration
NHEK cells (Lonza, Walkersville, MD) were used in this assay.
The cells were plated in 24 well plates at a density of 1.5610
5
cells/well. The next day the confluent cultures were wounded
using a pipette tip, washed 3 times with PBS and fed with fresh
culture media. Control wells contained the basal serum free media
(Lonza, Walkersville, MD). Media in the experimental wells was
supplemented with 0.5 nM PDP (UN1-UN3). HB-EGF was added
to media as a positive control. After the addition of the fresh
media, the cells were placed onto climate-controlled microscope
stage and wound closure was monitored for 4 hours. Wound sizes
were measured at the time of injury and 4 h pot-injury using
ImageJ software (available from NIH) and relative wound closure
was then determined.
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Cell proliferation assays were performed using CEC, NHEK
and Hacat cells. For the proliferation assay the cells were plated at
2610
3 cells per well in 3648 well plates in basal media. One day
after plating the media in control wells was replaced with media
containing 1% serum for CEC or Hacat cells, or with serum free
media with bovine pituitary extract and HB-EGF for NHEK.
Basal media in experimental wells was supplemented with the
platelet extracts (0.1–200 ng/mL) or the peptides added at
100 nM (comb1) or 250 nM (UN3). The cells were fed every
other day and counted at day 5 post-plating. Three wells were
used per condition and each experiment was performed in
triplicate.
In vitro endothelial morphogenesis
This assay was performed as described with minor modifications
[10]. Briefly, CEC or HMDEC 7610
4 cells/cm
2 were plated on
growth factor reduced Matrigel at (GFR Matrigel, BD Biosciences,
Bedford, MA) in DMEM supplemented with 1% BCS in the
presence or absence of platelet extracts, PDP or EDP added
directly to basal media or mixed with GFR Matrigel prior to gel
polymerization 100 nM (comb1) or 250 nM (UN peptides).
Purified recombinant basic FGF (FGF-2) or VEGF (R&D Systems,
Minneapolis, MN) were used as positive controls. BCEC
endothelial sprout formation was monitored at 7 h post-plating;
HMDEC sprout formation was monitored at 4 h. Cell imaging
was performed using an Axiovert 200 M microscope equipped
with 106objective lenses (Carl Zeiss MicroImaging, Thornwood,
NY). Images were analyzed using ImageJ software (available from
NIH). The total sprout length per field were measured from
several experiments performed in duplicate or triplicate and
quantified as described [10].
In vivo wound healing studies
Balb/c mice were pre-treated with two doses of cyclophosph-
amide (CY) dissolved in sterile saline and administered by IP
injection: 150 mg/kg 4 days and 100 mg/kg 1 day before
wounding in order to delay wound healing as described previously
[14]. Three control mice received the wounds as described below
and were treated with daily application of carboxymethylcellulose
(CMC), which was used in this study as a vehicle for peptide
application.
Full thickness cutaneous, excisional head wounds were created
in the following way. The mouse heads were depilated (Nair,
Carter-Wallace, New York, NY) 15–24 h prior to wounding. For
wounding procedures and during all manipulations and treatments
the mice were anesthetized by an intraperitoneal injection of a
ketamine-xylazine cocktail (90 mg/kg ketamine and 10 mg/kg
xylazine). Full thickness excisional wounds were made with sterile
4 mm punch biopsy tool, sterile scissors and forceps. Immediately
after injury wounds were dressed (Tegaderm, 3 M St. Paul, MN).
The peptides were suspended in 3% CMC in PBS at concentra-
tion of 1 mg/mL (comb1) or 284 mg/mL (UN3) and injected
under the dressings using 25G needle at 24 h post-injury. CMC or
Regranex gels were used as negative and positive controls,
respectively. All treatments were applied daily and dressings were
changed as necessary.
Tissue harvesting and staining
Collection of animal tissues was performed at 5 or 10 days post-
injury. The animals were euthanized by CO2 inhalation and
wounds, together with underlying tissues and approximately 5 mm
of intact dermis surrounding the wound were then excised. The
wounds then were bisected through the midline. One half of the
tissue then was placed in 10% phosphate buffered formalin (Fisher
Scientific, Asheville, NC), fixed for 24 h, embedded in paraffin, cut
into 5 mm thick sections and stained with hematoxylin and eosin
(H&E) or Trichrome stain (ThermoScientific, Asheville, NC) as
per manufacturers instructions. The other half was embedded into
O.C.T compound (Sakura Finetek USA, Inc., Torrance, CA
90501,) and frozen on dry ice. After freezing the tissues were cut
into 5 mm thick sections and stained as described below. Imaging
of Trichrome and H&E stained sections was performed with Zeiss
Axiophot microscope (Carl Zeiss MicroImaging, Thornwood, NY)
using 56objective lens. The images were digitally registered and
merged using Adobe Photoshop CS2 (Adobe, San Jose, CA).
Immunohistochemical staining of frozen sections
Briefly, the sections were warmed up the room temperature for
10 min, fixed with DMEM-containing 4% paraformaldehyde and
permeabilized with 0.1% Triton X-100 for 90 seconds. After
blocking for 2 h with 5% goat serum, sections were incubated with
rat anti-CD31 antibodies (BD Pharmingen) (1:500) and rabbit
anti-HSPG (1:200) overnight at 4uC. Sections then were washed
and co-incubated with fluorescently labeled anti-rat Alexa 546,
anti-rabbit Alexa 488 secondary antibodies (Molecular Devices,
Sunnyvale, CA) both at 1:200 dilution and 16.2 mM Hoechst
33342 (Molecular Probes, Invitrogen, Carlsbad, CA) for 2 h at
room temperature. After a triple wash with PBS, stained sections
were mounted with PermaFluor (Lab Vision Corporation,
Fremont, CA). Visualization of the slides was performed with
Axiovert 200 M microscope (Carl Zeiss MicroImaging, Thorn-
wood, NY) using 56and 106objective lenses.
Analysis of wound healing and quantification of
angiogenic response
Images of H&E as well as trichrome-stained sections obtained at
low magnification were merged using Adobe Photoshop CS2
(Adobe, San Jose, CA). The merged images were then analyzed by
two independent observers blinded to all treatment groups. To
estimate the degrees of wound healing, we used a histologic scale
shown in Table 1 where epithelialization and granulation tissue
formation were analyzed and assigned a score in a blinded fashion.
To quantify tissue responses to peptide treatments post injury,
we assessed angiogenic activation as well as re-epithelialization.
We used frozen sections stained with anti-CD31 (red) and anti-
HSPG (green) antibodies as described above. The areas of
antibody co-localization (yellow) representing blood vessels were
quantified using ImageJ software and image co-localization tool.
Data analysis and statistics
All in vitro experiments were performed at least triplicate.
Counts obtained in cell proliferation assay, in 2D in vitro
morphogenesis assay and a scratch wound model were recorded
Table 1. Modified histology scale for wound grading.
Score Criteria
1 No epithelialization, no granulation tissue formed
2 No epithelialization, granulation tissue poorly formed
3 Complete epithelialization, poor granulation tissue formation
4 Complete epithelialization, well-defined granulation tissue
doi:10.1371/journal.pone.0032146.t001
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mond, WA). Results are presented as mean 6 SEM. Results of
NHEK proliferation assays using fractionated platelet extracts was
plotted using the ggplot2 package of R 2.10.1. Statistical
significance of the in vitro findings was analyzed by two-tailed t-
test. The value of p,0.05 was considered significant.
In vivo experiments were performed three times using three to
five animals per each experimental group, with total number of
animals of 9 to 15 per treatment. Wound healing rates determined
using wound healing grades as described above and were manually
recorded using Microsoft Excel (Microsoft, Redmond, WA). Data
analysis was performed using one-way ANOVA test, statistical
significance of the findings was then confirmed by Dunnett’s and
Student-Newman-Keuls tests.
Results
Characterization of platelet extracts lots and
identification of extract-derived peptides
The platelet extracts were prepared as described in Materials
and Methods and subjected to SDS-PAGE followed by Coomassie
staining and mass spectrometry. Results reveal that different lots of
platelet extracts contains a complex mixture of over a dozen
proteins, including but not limited to albumin, immunoglobulins
and cytoskeletal components, including myosin IIB (Figure 1 A-B).
Interestingly, and as shown in Figure 1, some preparations were
nearly free of myosin IIB, suggesting that this extract was relatively
poor in platelet components when standardized for mg protein
present/ml extract. In these platelet-poor preparations, plasma
proteins were enriched in albumin, fibrinogen and transferrin as
judged by MS/MS spectrophotometric analysis.
Biological activity of the platelet extracts was then evaluated in
vitro assays. As shown in Figure 2 all three lots of the extracts
stimulated proliferation of transformed keratinocytes (Hacat cells).
The effectiveness of the extracts preparation of different lots varied
significantly. Lot 1 preparation of the extracts added to cell culture
media at 1 mg/mL induced a three-fold increase in keratinocyte
proliferation as compared to serum-stimulated controls. This
increase of epithelial proliferation was superior to what was
achieved in the presence of HB-EGF used in this study as a positive
control. Lower doses of this extract preparation were less effective,
inducing a 53% increased proliferation. Lots 2 and 3 of the extracts
induceda 50%increase inHaCatcellproliferationwhileaddition of
1 mg/mL extract from lots 2 and 3 have modest stimulatory effects
on endothelial proliferation (Figure 2 and data not shown).
Based on these observations, we selected plasma-derived and
platelet extracts that possessed pronounced biological activity and
reasoned that further fractionation and enrichment of the specific
cell stimulating activities might enable our identification of the
biochemical entities, which promoted cell growth, migration and/
or angiogenesis. To these ends, we performed gel filtration (G-150)
and ion-exchange chromatography (DEAE cellulose). Gel filtra-
tion allowed for the purification of several fractions including one,
fraction 22 (Figure 3A), which when applied to keratinocytes at
200 ng/ml induced a 40% increase in their proliferation rate
(Figure 3 B). Further fractionation using ion-exchange chroma-
tography and elution of the proteins with 0.5 M NaCl led to
Figure 1. Characterization of protein composition of human
platelet extracts. A – Coomassie Blue stained SDS-PAGE demonstrat-
ing the complexity of protein composition of platelet lysate and
extracts. B – Western blot analysis of platelet lysate and extracts
revealing the presence of myosin in lots 2 and 3, but not lot 1 extract or
platelet lysate. 1- platelet lysate; 2 – platelet extract lot 1, 15 mg/mL; 3 -
platelet extract lot 1, 50 mg/mL; 4 - platelet extract lot 2, 15 mg/mL; 5 -
platelet extract lot 2, 50 mg/mL; 6 - platelet extract lot 3, 15 mg/mL; 7 -
platelet extract lot 3, 50 mg/mL.
doi:10.1371/journal.pone.0032146.g001
Figure 2. Platelet extracts stimulate epithelial proliferation in
vitro. Hacat cells were plated as described in Materials and Methods in
the presence or absence of at 1 mg/mL of proteins from platelet extracts
(Lots 1–3). Relative proliferation compared to control is shown. Data
presented as mean +/2 standard error; * - indicates p,0.05.
doi:10.1371/journal.pone.0032146.g002
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responses. These proteins added to the cells at 50 ng/ml induced
more than two-fold increase in keratinocyte proliferation
(Figure 3B) and an enhancement of endothelial migration.
As shown in Figure 3A, fractionation of platelet extracts
significantly reduced the complexity of the protein mixtures and
eliminated all high molecular weight proteins. Mass spectrometry
analysis of the protein bands with molecular weight below 150 kd
revealed several unnamed (UN) protein fragments, some of which
possess sequence identity to fragments of human thrombin.
Corresponding peptides were synthesized at TUCF. The peptides
sequences are as follows: NH2-ELLESYIDGR-Amide – UN1;
NH2- TATSEYQTFFNPR-Amide – UN2; NH2-ELLE-
SYIDGRPTATSEYQTFFNPR-Amide – UN3. All three peptides
stimulated angiogenesis in vitro as well as epithelial migration.
However, as shown in Figure 4 a combinatorial UN3 peptide was
a more potent stimulator of cellular responses than either UN1 or
UN2 peptides. It induced 2.5-fold increase in a total tube length
and a 3-fold increase in epithelial responses to injury (Figure 4 A
and B). Therefore, we chose to use this peptide for our further in
vitro and in vivo experiments.
Identification of endothelial ECM-derived peptides
Endothelial ECM-derived peptides were isolated as described
[10]. In total we have synthesized thirteen peptides. However, in
Figure 3. Characterization of Lot 1-derived fractions. A – silver
stained SDS-PAGE demonstrating reduction of composition complexity
following gel filtration and ion exchange chromatography. 1 - MW
markers, 2 – unfractionated lot 1, 3- fraction 22, 4 – proteins eluted with
0.5 M NaCl. B – fractionated platelet extracts retain their biological
activity toward epithelial cells. For proliferation assay NeoNHEK were
plated in keratinocyte growth medium the presence or absence of
unfractionated proteins from Lot 1 or fractions of Lot 1 (0.1–200 ng/mL)
as indicated. HB-EGH (10 ng/mL) was used as positive control. Relative
proliferation compared to control is shown. Data are presented as mean
+/2 standard error.
doi:10.1371/journal.pone.0032146.g003
Figure 4. Platelet rich plasma derived peptides stimulate in
vitro angiogenesis and epithelial responses to injury. A – In vitro
angiogenesis assay. Human capillary endothelial cells were plated on
growth factor reduced Matrigel as described in Materials and Methods.
The media was supplemented with either DMEM supplemented with
1% BCS or 250 nM of UN1, UN2 or UN3 peptides. Cells that have
received DMEM/1% in the presence of 10 ng/ml VEGF served as positive
control. Total tube length was measured at 4 h post-plating. Relative
tube length compared to control is shown. B – In vitro epithelial wound
healing assay. NHEK cells were plated and injured as described in
Material ad methods. The following experimental conditions were used:
basal keratinocyte growth media (control), 10 ng/ml HB-EGF (positive
control), 0.5 nM UN1, UN2 or UN3 peptides. Relative wound closure is
shown. Data are presented as mean +/2 standard error; * - indicates
p,0.05.
doi:10.1371/journal.pone.0032146.g004
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containing fragments of both tenascin X and fibrillin 1. This
peptide was chosen based on our previously published data
describing its stimulatory activity toward endothelial cells in vitro
[10].
ECM and platelet extracts-derived peptides stimulate
cellular responses in vitro
Our previous study demonstrated that comb1 peptide had a
remarkable ability to stimulate in vitro angiogenesis and increased
the rates of endothelial tube formation by 2-fold [10]. In this work
we wanted to determine whether a combination of the UN3 and
comb1 could stimulate endothelial responses even further. This
was performed using in vitro tube formation assays as described in
Materials and Methods. Results reveal that the peptides used alone
or in combination induce a 2–3 fold increase in the total length of
tubes formed by capillary endothelial cells plated on growth factor-
reduced Matrigel as compared to control cells, plated in the
presence of serum (Figure 5A).
For the proliferation assays we used transformed human
keratinocytes. As shown in Figure 5B, comb1 peptide significantly
(75%) increased the rate of epithelial (Hacat cells) proliferation,
UN3 was also effective and increased the levels of keratinocyte
proliferation by 55%. A similar increase of proliferation was found
for cells treated with both comb1 and UN3. Importantly, the
peptides were equally effective as HB-EGF, which was used as a
positive control.
Cyclophosphamide treated mice have delayed cranial
cutaneous wound healing
In vitro studies demonstrate pro-angiogenic and pro-proliferative
effects of plasma- and ECM-derived peptides, suggested that these
bioactive molecules may have wound healing potential in vivo. In
ordertotestthis,weuseda mousemodelofimpairedwoundhealing
where Balb/c mice are pre-treated with two doses of CY at days 4
and 1 before wounding [14]. Impairment of wound healing in CY-
treated mice has been observed previously [15–17]. However, these
studies employed models of wound healing distinct from cranial
dermal wounds. Therefore, first we tested whether dermal cranial
wound healing would indeed be delayed in CY-treated animals. In
order to estimate the degrees of healing we created and treated the
wounds described in Materials and Methods, and used the grading
scheme shown in Table 1 to evaluate the wound healing.
Histological evaluation of the degree of wound healing revealed
that CY significantly impaired cranial dermal wound healing
(Figure 6A–B and Figure 7). Interestingly, this delay was more
prominent at 10 days post injury and corresponded to a decrease in
the number of blood vessels within the wound beds of CY treated
animals compared with controls (Figures 7 and 8).
The peptides stimulate wound healing in CY treated
mice
Next we sought to evaluate whether the peptides could reverse
the effects of CY and improve impaired wound healing in CY-
treated Balb/c. The effects of the peptides on excisional wound
healing were studied in 5 and 10 day long assays. The peptides were
suspended in carboxymethylcellulose (CMC) as described above
and applied into the wounds daily. CMC without the peptides was
used as a control and Regranex served as a positive control.
As shown in Figures 6 and 7, single peptides as well as their
combination improved wound healing in CY-treated Balb/c mice.
As evident from Trichrome stained tissue sections harvested five
days after injury, the wounds in mice injected with CY alone did
not display significant epithelial coverage and had only a minor
accumulation of granulation tissue. At the same time wounds in
peptide treated animals began to epithelialize and form granula-
tion tissue. Collagen deposition within 5-day old wound beds was
minimal in either control or peptide-treated animals.
At a later time point (10 days) there were significant differences
in healing between the treatment groups. While wounds treated
with CMC alone remained largely unepithelialized, wounds
treated with the peptides or Regranex were covered with well-
defined and stratified epithelium (Figures 6 and 7). Moreover,
peptide-treated wounds were characterized by better-defined
granulation tissue and by significant collagen deposition, especially
in wounds treated with UN3 and a combination of UN3 and
comb1 (Figure 6 E, Figure 8 D). Quantitative evaluation of H&E
stained sections (Figure 7) confirmed that there were significant
improvement of healing of wounds treated with the peptides as
compared to controls. Interestingly, combination of the peptides
(UN3+comb1) (Figures 6 and 7) further improved the outcome,
Figure 5. ECM-and platelet extract-derived peptides stimulate
in vitro angiogenesis and epithelial proliferation. A – In vitro
angiogenesis assay. Bovine capillary endothelial cells were plated on
the surface of growth factor reduced Matrigel in the presence or
absence of 100 nM comb1 or 250 nM UN3, or the two peptides
combined. DMEM supplemented with 1% BCS was used as control, cells
that have received DMEM/1% supplemented with 10 ng/ml bFGF or
VEGF served as positive control. Total tube length was measured at 7 h
post-plating. Relative tube length compared to control is shown. B – In
vitro epithelial proliferation assay. Hacat cells were plated as described
in Materials and Methods. The peptides were added at 100 or 250 nM
(comb1 and UN3 respectively). Cell counting was performed at 5 days
post-plating. Relative cells numbers as compared to control are shown.
Data are presented as mean +/2 standard error; * - indicates p,0.05.
doi:10.1371/journal.pone.0032146.g005
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improvement of wound healing in the presence of the peptides was
superior to that seen in Regranex-treated wounds.
Stimulation of wound healing angiogenesis by platelet
rich plasma and ECM-derived peptides
As shown previously, ECM-derived comb1 significantly im-
proved endothelial proliferation, morphogenesis and responses to
injury in vitro [10]. In addition, the data presented in this work
demonstrated that plasma-derived UN3 had similar biological
activity. Therefore we wanted to determine whether the wound
healing stimulation by the peptides was linked to their pro-
angiogenic properties. As described in Materials and Methods, in
order to determine blood vessel density we performed immuno-
staining of frozen wound tissues with anti-CD31 and anti-HSPG
antibodies. Analysis of CD31 and HSPG co-localization corre-
sponding to blood vessels demonstrated that combined (com-
b1+UN3) peptides indeed stimulated wound healing angiogenesis
(Figure 9). The wounds treated with the peptides had twice as
many blood vessels as wounds in animals treated with CY alone
(Figure 9). Importantly, the peptides reversed negative effects of
CY injections on wound angiogenesis: the number of blood vessels
within the wounds of CY-injected mice treated with peptides was
equal to that of control (non-CY-treated) animals (Figure 9).
Peptides promote epithelialization and basement
membrane formation
Restoration of epithelial integrity is a critical step during wound
healing. We assessed epithelial thickness and a degree of basement
membrane formation in both control and peptide treated wounds.
As shown in Figures 6 and 8 wounds treated with UN3 and comb1
combined had increased epithelial thickness at days 5 and 10 post-
injury compared to CMC treated controls, and wounds treated
with UN3 or comb1 separately.
Basement membrane formation was assessed using Trichrome
stained histological sections of 5 days-old wounds. Results revealed
the presence of well-defined basement membrane layer in peptide
or Regranex treated but not in CMC treated wounds (Figure 8).
Figure 6. Histological evaluation of wound healing effects of the peptides in CY-treated Balb/c mice. Animals were either wounded and
treated with CMC (A) or injected with CY 1 and 4 days prior to injury, wounded and treated with CMC alone (B), with Regranex (C), with UN3 (D),
comb1 (E) or a combination of UN3 and comb1 (F). Wounds were excised at day 10 post-injury, formalin-fixed, sectioned and stained with
haematoxylin and eosin. Dotted line delineates the wound bed. Scale bar 500 mm.
doi:10.1371/journal.pone.0032146.g006
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In our previous study we described and characterized in vitro
effects of several pro-angiogenic peptides derived from endothelial
ECM degraded by bacterial collagenase [10]. In this work we
tested whether comb1 peptide - the most active EDP identified in
vitro could stimulate cellular responses to injury in vivo.
Furthermore, we have described and characterized a novel
biologically active peptide derived from human platelet-rich
plasma, which we termed UN3.
Platelet extracts used in this study were prepared from human
donor platelet rich plasma. SDS-PAGE analysis (Figure 1)
demonstrated the presence of multiple protein bands in all three
extract lots studied. The complexity of extract protein composition
is well known as platelet releasate have been demonstrated to
contain 315 proteinaceous entities [18], including several modu-
lators of cellular responses such as vascular endothelial growth
factor, epidermal growth factor, and basic fibroblast growth factor.
These proteins, as well as several less known bioactive moieties, are
responsible for stimulatory effects that platelet products have on
endothelial and epithelial cells which are described in the literature
[19–21]. Similarly, our experiments using three different platelet
extract preparations also demonstrated that endothelial and
epithelial cell proliferation and migration can be stimulated in
the presence of the extracts (Figure 2 and Figure 3). While all three
lots used in this study had stimulatory effects on cells, we observed
a high degree of lot-to-lot variability. For example, lot 1
preparation induced a three-fold increase of keratinocyte prolif-
eration, while lots 2 and 3 used at identical protein concentration
only moderately enhanced cellular responses by 30–50%. This
variability of the biological activity of platelet products correlated
with variations in their chemical compositions which were both
observed in this study (Figure 1) and reported by other groups
[22]. Specifically, different lots of platelet preparations vary in the
abundance of components of platelet cytoskeleton (Figure 1B),
cytokines and growth factors [22]. In this study we wanted to
overcome lot variability of platelet extracts and identify novel
biologically active moieties (peptides) possessing pro-angiogenic
and wound healing properties.
The peptides were identified using the methodology similar to
that used previously in our laboratory to isolate a novel beta actin-
specific capping protein [12]. Specifically, we subjected platelet
extracts to gel filtrationand ion-exchange chromatography followed
by mass spectrometry to allow for protein identification. In addition
to well-known platelet extract components, we identified two novel
small fragments which we named UN1 and UN2. In addition we
created a combinatorial peptide UN3, which contained amino acids
present in both UN1 and UN2. In vitro testing of the peptides
revealed that all of them had stimulatory effects of cellular
responses, however, UN3 peptide was more biologically active
compared to UN1 or UN2. We also tested whether this peptide
could be combined with extracellular matrix derived peptide
comb1, which was identified in our previous study [10].
Figure 7. Quantitative evaluation of wound healing responses
induced by the peptides in CY-treated mice. Wounds were
created, treated, fixed and stained as described in Material and Methods
and Figure 5. Grades were assigned to each wound based on criteria
described in Table 1. At least 5 wounds were graded for each condition.
Data are presented as mean +/2 standard error; * - indicates p,0.05
(compared to CY+CMC treated animals).
doi:10.1371/journal.pone.0032146.g007
Figure 8. Effects of the peptides on collagen and basement
membrane deposition during wound healing. Trichrome was
used to stain wounds excised at day 5 post-injury. All the animals were
injected with CY prior to injury. Representative sections of wounds
treated with CMC alone (A), UN3 (B), comb1 (C) or a combination of
UN3 and comb1 (D). Images were taken at 56 objective lens and
merged using Adobe Photoshop CS2. Arrows indicate newly deposited
basement membrane. Scale bar 200 mm.
doi:10.1371/journal.pone.0032146.g008
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combination had stimulatory effects on cellular proliferation and
morphogenesis in vitro (Figure 4A and B).
Next we sought to determine whether the peptides would retain
their properties in vivo. This was tested using a mouse model of
CY treated Balb/c mice that are characterized by impaired wound
healing [14]. All mice used in this study received cranial dermal
punch biopsies. This type of wound was used in order to minimize
the wound contraction, encourage granulation tissue deposition/
epithelialization and thus make mouse wound healing more
resembling that of ‘‘tight skinned’’ animals including humans
[23,24]. Cranial wounds in CY-treated mice heal slower than in
healthy counterparts (Figure 7). The peptides, especially when
used in combination, significantly improved wound healing in CY-
treated mice. In these animals, the peptides are more efficient than
clinically used Regranex gel. Other important advantages of the
peptides over PDGF and other wound healing growth factors
include the relative simplicity of their synthesis and production in
large quantities at relatively low cost, and their potential stability
within the protease-rich wound environment due to a lack of the
protease- binding sites within their structures. Furthermore,
compelling pre-clinical in vitro observations point to the marked
efficacy of these engineered wound healing peptides compared to
peptide growth factor treatment of wounds in vitro [10].
Our in vitro experiments with endothelial cells revealed the pro-
angiogenic potential of the peptides. Therefore, we tested whether
similar effects could be achieved in vivo. Results revealed that the
peptides could stimulate blood vessel formation within the wound
bed. Similar pro-angiogenic effects were described for laminin-
derived peptides [25]. These peptides induced an increase in both
number and size of blood vessels at day 4 post-injury. In our
experiments the effects on angiogenesis were more pronounced at
a later time point – 10 days post-wounding (Figure 9). Interest-
ingly, one of bioactive collagen IV fragments (Col4-1) identified in
our previous study [10], did not enhance angiogenesis of wound
healing in vivo.
Analysis of Trichrome stained sections of mouse wounds excised
at day 5 post-injury showed increased epithelialization accompa-
nied by enhanced basement membrane deposition in the presence
of the peptides (Figure 8 E–H). The increase in ECM deposition
could be one of the mechanisms by which the peptides stimulate
wound healing. Other mechanisms are likely to include activation
of ECM receptors, particularly integrins avb3 and a5b1 which
were shown to bind to biologically active laminin-derived peptides
and induce an increase in migration of both endothelial and
epithelial cells [25].
Interestingly, combining the peptides before addition to the cells
in vitro did not have synergistic effects (Figure 5) possibly due to
direct competition between the peptides for respective receptor on
the cell surface. In vivo however, the effects were more
pronounced when both peptides were applied simultaneously
(Figures 6 and 7). This can be linked to the fact that unlike in vivo
there are more cellular receptors in relation to the peptides;
therefore there is a lower chance for peptide-peptide competition.
In conclusion, we have shown that the peptide derived as a
result of degradation of endothelial extracellular matrices and a
peptide derived from human plasma stimulate wound healing in
vivo (Figures 6 and 7). The mechanism of this stimulation is
currently being investigated.
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